Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.

According to our (Global Info Research) latest study, the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size was valued at US$ 2225 million in 2023 and is forecast to a readjusted size of USD 2958 million by 2030 with a CAGR of 4.2% during review period.

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs key players include Merck, Eisai, Mundipharma, etc. Global top three manufacturers hold a share over 50%.

North America is the largest market, with a share about 50%, followed by China, and Europe both have a share about 35 percent.

In terms of product, 5-HT3 Inhibitors is the largest segment, with a share over 60%. And in terms of application, the largest application is Moderately Emetogenic Chemotherapy, followed by Highly Emetogenic Chemotherapy, Low Emetogenic Chemotherapy, etc.

This report is a detailed and comprehensive analysis for global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2019-2030

Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2019-2024

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Chemotherapy Induced Nausea and Vomiting (CINV) Drugs

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Heron Therapeutics, Roche, Mylan, Tesaro, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
5-HT3 Inhibitors
NK1 Inhibitors
Other

Market segment by Application
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other

Major players covered
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Chemotherapy Induced Nausea and Vomiting (CINV) Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs, with price, sales quantity, revenue, and global market share of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs from 2019 to 2024.

Chapter 3, the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs.

Chapter 14 and 15, to describe Chemotherapy Induced Nausea and Vomiting (CINV) Drugs sales channel, distributors, customers, research findings and conclusion.